PET/CT in Psoriatic Arthritis

NCT01654198 | Completed

• 1 other identifier: 815253
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.

Conditions

Psoriatic Arthritis

Outcome Measures

Primary Outcomes (1)

• Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses.

  At the discretion of the PI

Secondary Outcomes (1)

• Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP.

  At the discretion of the PI

Study Arms (1)

Psoriatic arthritis

Radiation: FDG-PET/CT scan

Interventions

FDG-PET/CT scan RADIATION

FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.

Psoriatic arthritis

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with psoriatic arthritis defined by CASPAR criteria and active joint disease.

You may qualify if:

• Age 18-80,
• active psoriatic arthritis (joint or enthesis inflammation)

You may not qualify if:

• Diabetes,
• pregnant,
• no active PsA

Sponsors & Collaborators

• University of Pennsylvania: lead

Study Sites (1)

University of Pennsylvania Division of Rheumatology

Philadelphia, Pennsylvania, 19104, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Plasma, Serum, and Plasma Cells

MeSH Terms

Conditions

Arthritis, Psoriatic

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Alexis R Ogdie, MD, MSCE

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2012
• First Posted: July 31, 2012
• Study Start: July 1, 2012
• Primary Completion: October 2, 2018
• Study Completion: October 2, 2018
• Last Updated: December 8, 2020

Record last verified: 2020-12

Locations

US (1)